The Apex Times
Above the Noise
Business Wire
BusinessChevron’s Angola discovery raises hopes for an added growth pipelineThe Apex TimesBusinessJPMorgan turns cautious on Klarna as weaker outlook and management plans weigh on sharesThe Apex TimesBusinessTesla teases a Cybercab launch event, but TSLA shares do not appear to be reacting yetThe Apex TimesBusinessYahoo Finance frames decade-long outcome for Mastercard investors using a $1,000 “buy and hold” exampleThe Apex TimesBusinessa16z partner Josh Elman targets California politics after startups face a “push away” risk, says the state already lost Tesla and SpaceX HQsThe Apex TimesBusinessStock Forecast: Eli Lilly’s $1 Trillion Moment Isn’t the End of the Story, Traders Are Being ToldThe Apex TimesBusinessWall Street split calls across healthcare and China tech, with Moderna upgraded and Baidu downgradedThe Apex TimesBusinessToyota Racing launches a four-episode YouTube series that pairs NASCAR pit-stop intensity with a creator-style formatThe Apex TimesBusinessGoogle showcases three creatives’ studio-style campaigns built with unlimited access to Google FlowThe Apex TimesBusinessGM’s buyback surge has cooled, while Ford looks to be gaining groundThe Apex TimesBusinessMarvell jumps after a reported $12.2 billion Google warrant disclosure, while Broadcom slips 3%The Apex TimesBusinessNetflix taps Paolla Oliveira and Fabiula Nascimento for new Rio-shot melodrama “Imperfect Mother”The Apex TimesBusinessChevron’s Angola discovery raises hopes for an added growth pipelineThe Apex TimesBusinessJPMorgan turns cautious on Klarna as weaker outlook and management plans weigh on sharesThe Apex TimesBusinessTesla teases a Cybercab launch event, but TSLA shares do not appear to be reacting yetThe Apex TimesBusinessYahoo Finance frames decade-long outcome for Mastercard investors using a $1,000 “buy and hold” exampleThe Apex TimesBusinessa16z partner Josh Elman targets California politics after startups face a “push away” risk, says the state already lost Tesla and SpaceX HQsThe Apex TimesBusinessStock Forecast: Eli Lilly’s $1 Trillion Moment Isn’t the End of the Story, Traders Are Being ToldThe Apex TimesBusinessWall Street split calls across healthcare and China tech, with Moderna upgraded and Baidu downgradedThe Apex TimesBusinessToyota Racing launches a four-episode YouTube series that pairs NASCAR pit-stop intensity with a creator-style formatThe Apex TimesBusinessGoogle showcases three creatives’ studio-style campaigns built with unlimited access to Google FlowThe Apex TimesBusinessGM’s buyback surge has cooled, while Ford looks to be gaining groundThe Apex TimesBusinessMarvell jumps after a reported $12.2 billion Google warrant disclosure, while Broadcom slips 3%The Apex TimesBusinessNetflix taps Paolla Oliveira and Fabiula Nascimento for new Rio-shot melodrama “Imperfect Mother”The Apex TimesBusinessChevron’s Angola discovery raises hopes for an added growth pipelineThe Apex TimesBusinessJPMorgan turns cautious on Klarna as weaker outlook and management plans weigh on sharesThe Apex TimesBusinessTesla teases a Cybercab launch event, but TSLA shares do not appear to be reacting yetThe Apex TimesBusinessYahoo Finance frames decade-long outcome for Mastercard investors using a $1,000 “buy and hold” exampleThe Apex TimesBusinessa16z partner Josh Elman targets California politics after startups face a “push away” risk, says the state already lost Tesla and SpaceX HQsThe Apex TimesBusinessStock Forecast: Eli Lilly’s $1 Trillion Moment Isn’t the End of the Story, Traders Are Being ToldThe Apex TimesBusinessWall Street split calls across healthcare and China tech, with Moderna upgraded and Baidu downgradedThe Apex TimesBusinessToyota Racing launches a four-episode YouTube series that pairs NASCAR pit-stop intensity with a creator-style formatThe Apex TimesBusinessGoogle showcases three creatives’ studio-style campaigns built with unlimited access to Google FlowThe Apex TimesBusinessGM’s buyback surge has cooled, while Ford looks to be gaining groundThe Apex TimesBusinessMarvell jumps after a reported $12.2 billion Google warrant disclosure, while Broadcom slips 3%The Apex TimesBusinessNetflix taps Paolla Oliveira and Fabiula Nascimento for new Rio-shot melodrama “Imperfect Mother”The Apex TimesBusinessChevron’s Angola discovery raises hopes for an added growth pipelineThe Apex TimesBusinessJPMorgan turns cautious on Klarna as weaker outlook and management plans weigh on sharesThe Apex TimesBusinessTesla teases a Cybercab launch event, but TSLA shares do not appear to be reacting yetThe Apex TimesBusinessYahoo Finance frames decade-long outcome for Mastercard investors using a $1,000 “buy and hold” exampleThe Apex TimesBusinessa16z partner Josh Elman targets California politics after startups face a “push away” risk, says the state already lost Tesla and SpaceX HQsThe Apex TimesBusinessStock Forecast: Eli Lilly’s $1 Trillion Moment Isn’t the End of the Story, Traders Are Being ToldThe Apex TimesBusinessWall Street split calls across healthcare and China tech, with Moderna upgraded and Baidu downgradedThe Apex TimesBusinessToyota Racing launches a four-episode YouTube series that pairs NASCAR pit-stop intensity with a creator-style formatThe Apex TimesBusinessGoogle showcases three creatives’ studio-style campaigns built with unlimited access to Google FlowThe Apex TimesBusinessGM’s buyback surge has cooled, while Ford looks to be gaining groundThe Apex TimesBusinessMarvell jumps after a reported $12.2 billion Google warrant disclosure, while Broadcom slips 3%The Apex TimesBusinessNetflix taps Paolla Oliveira and Fabiula Nascimento for new Rio-shot melodrama “Imperfect Mother”The Apex Times
Back to front
Merck and Moderna report Phase 3 topline gains for INTerpath-001 in resected stage IIB-IV melanoma
The Apex Times

THE APEX TIMES

Business/The Apex Times/Aug 19, 6:54 AM EDT

Merck and Moderna report Phase 3 topline gains for INTerpath-001 in resected stage IIB-IV melanoma

The companies said their Phase 3 trial combining Moderna’s intismeran autogene with Merck’s KEYTRUDA met key recurrence and distant metastasis endpoints in patients whose tumors were completely removed.

2 min readEditor-approved Apex article

Merck and Moderna said they have generated positive topline results from their Phase 3 INTerpath-001 trial testing a combination therapy in patients with completely resected stage IIB-IV melanoma. The treatment pairs Moderna’s intismeran autogene with Merck’s KEYTRUDA, an immunotherapy designed to help the immune system recognize and attack cancer cells.

In a joint announcement dated August 19, 2026, the companies said the study met two key efficacy endpoints: recurrence-free survival (RFS) and distant metastasis-free survival (DMFS). RFS measures the length of time patients live without the melanoma returning, while DMFS tracks time until cancer spreads to distant sites.

The trial population includes people with stage IIB-IV melanoma whose tumors were completely removed, placing the study in the adjuvant setting. In adjuvant trials, sponsors generally focus on whether a therapy can reduce the risk of recurrence after surgery, particularly in higher-risk stages where microscopic disease may remain.

Merck noted in the release that it is known as MSD outside the United States and Canada, reflecting how the companies brand the same corporate entity across markets. Moderna trades on the Nasdaq under the ticker MRNA, while Merck trades as MRK on the NYSE.

KEYTRUDA is a well-established anti-PD-1 therapy. In combination with a next-generation messenger RNA (mRNA)-based approach, INTerpath-001 reflects a broader industry strategy of pairing immunotherapies with individualized or immune-modulating components to improve outcomes for patients at high risk of recurrence.

For Moderna, the readout is another attempt to translate mRNA biology into oncology endpoints that matter clinically, beyond early-stage safety indicates. For Merck, the results provide data supporting the expansion of KEYTRUDA-based regimens into earlier and higher-risk disease settings, where preventing relapse is often a primary goal.

The companies’ announcement, as presented in the post, does not include additional details such as hazard ratios, p-values, median follow-up duration, or whether any specific subgroup results were emphasized. It also does not lay out safety findings, including the incidence of immune-related adverse events, which would typically be critical for interpreting a Phase 3 topline release.

Going forward, investors and clinicians will likely look for the full Phase 3 data set, including safety, the magnitude of benefit for RFS and DMFS, and any descriptive details about dosing and patient characteristics. A subsequent presentation or regulatory filing could further clarify how the combination compares with standard adjuvant options and whether the results persist across longer follow-up.

Why It Matters

  • Meeting RFS and DMFS in a resected melanoma population suggests the regimen may reduce both relapse risk and spread to distant sites, key outcomes in adjuvant oncology.
  • KEYTRUDA is often evaluated across multiple tumor settings, and a positive Phase 3 readout in stage IIB-IV resected melanoma could broaden the therapy’s potential use beyond advanced disease.
  • For Moderna, the results are a tangible validation point for an mRNA-based partner in oncology Phase 3 development, though the market will still need full efficacy and safety details.
  • The next catalyst will likely be more granular Phase 3 reporting, because topline endpoint success alone does not establish the level of clinical benefit or tolerability for routine use.

Sources

Key Facts

  • Merck and Moderna announced positive topline results from the Phase 3 INTerpath-001 trial in completely resected stage IIB-IV melanoma.
  • The combination tested in the study is Moderna’s intismeran autogene plus Merck’s KEYTRUDA.
  • The companies said the trial met recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) key endpoints.
  • The release frames the study in an adjuvant context, targeting patients after complete surgical removal of melanoma.
  • The announcement did not provide, in the available post, the magnitude of benefit (for example, hazard ratios) or detailed safety data.

Healthcare Related